The Alzheimer’s Disease‐Health Indices (AD‐HI): Development of Two Novel Outcome Measures for Use in Clinical Trials

In preparation for upcoming clinical trials, there is a clear need for improved clinical trial infrastructure to facilitate therapeutic assessment in Alzheimer’s disease, (AD), mild cognitive impairment (MCI), and related dementias. This research describes the development of a patient‐reported outcome measure, the Alzheimer’s Disease‐Health Index (AD‐HI), and a caregiver‐reported outcome measure, the Alzheimer’s Disease Caregiver‐Health Index (ADCR‐HI). These novel outcome measures were developed using large scale input from patients and caregivers and were designed in accordance with U.S. Food and Drug Administration (FDA) guidelines for use in drug labeling claims.